At HAI, Researchers Explore Diagnostic Potential of a Tau Tracer
AV1451 appears too weak to diagnose non-AD tauopathies.
6538 RESULTS
Sort By:
AV1451 appears too weak to diagnose non-AD tauopathies.
Newly discovered Aβ effects of this cancer drug may be unrelated to its previously known mechanism of action.
A free, open online course on rare forms of Alzheimer’s, Lewy body, and frontotemporal dementia aims to spread knowledge while harnessing social learning.
Some repeats seem to interfere with regulation of translation, causing dendrites to shrink.
A new procedure turns circulating immune cells into neurons. It could simplify how scientists make patient-specific disease models.
Proteolysis of other substrates, including Neuregulin, proceeds apace.
Healthy neurons tell astrocytes how to act. In the case of ALS, astrocyte signals spell trouble.
Results raise the tentative prospect that a medical food might have possible cognitive benefit early in disease.
Studies of two new mouse models find that this mutation leads to excitotoxicity, but little protein aggregation.
Souvenaid Trial Missed Primary, Partially Met Secondary Endpoints New Tack on Aβ Oligomer Role in Disease and Treatment The 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy was held March 9 to 12 in Athens, Greece. Research
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.
Thirteen “escapees” of childhood illness offer hope of finding protective variants that may pay dividends.
A NOVA special gets up close and personal with Alzheimer’s researchers and their patients, asking if this disease can be stopped.
Scientists report that the transcription factor NRF2 regulates tau expression, stimulating production of a protective isoform.
Neurogeneticists honored for their discoveries, especially of repeat expansions that cause ALS/FTD.
No filters selected